IQVIA Holdings (IQV) AI Stock Analysis

• Market Cap: $28.25B
• Dividend Yield: N/A
• Average Volume (3M): 2.64M
• Price to Earnings (P/E): 28.5
• Beta (1Y): 0.90
• Revenue Growth: 3.85%
• EPS Growth: -4.74%
• Country: US
• Employees: 89,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 3.42
• Shares Outstanding: 169,700,000
• 10 Day Avg. Volume: 1,589,285
• 30 Day Avg. Volume: 2,642,575
• PEG Ratio: 6.34
• Price to Book (P/B): 5.96
• Price to Sales (P/S): 2.38
• P/FCF Ratio: 18.89
• Enterprise Value/Market Cap: 1.51
• Enterprise Value/Revenue: 2.61
• Enterprise Value/Gross Profit: 9.93
• Enterprise Value/Ebitda: 12.29
• 1Y Price Target: $227.62
• Price Target Upside: 36.73% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16
• EPS Forecast (FY): 12.69
• Revenue Forecast (FY): $17.24B

• Rating: 59 Neutral
• Price Target: $174.00 ▲(4.52% Upside)
• Action: Reiterated Date: 02/07/26
• Date: Action: Reiterated 02/07/26

The score is driven primarily by decent underlying fundamentals but constrained by high leverage and recent margin/cash-flow pressure. Technicals are notably weak (below major moving averages with bearish momentum), while valuation is only moderate. The latest earnings call was constructive with solid FY2026 guidance and strong backlog, partially offset by margin pressure and rising interest expense.

Positive Factors

Diversified lifecycle services and recurring revenue

IQVIA’s integrated business model — CRO services, technology/analytics subscriptions, and commercial outsourcing — produces diversified, recurring revenue streams tied to multi‑year contracts and project pipelines. This reduces single‑cycle exposure, supports cross‑sell, and yields durable revenue visibility for 2–6+ months and beyond.

Strong bookings and large, visible backlog

A record $32.7B backlog and >$2.7B quarterly bookings provide meaningful revenue visibility and conversion runway. High backlog with a sizable portion expected in the next 12 months smooths near‑term top‑line risk, supports predictable utilization of CRO capacity, and underpins medium‑term organic growth.

Robust cash generation and FCF conversion

Consistent free cash flow (~$2.5B in 2025, near parity with adjusted earnings) demonstrates strong cash conversion across cycles. Reliable FCF supports targeted AI and capability investments, selective M&A, share repurchases, and gradual debt reduction while providing enduring financial flexibility versus peers.

Negative Factors

Elevated and rising leverage

IQVIA’s high leverage (total debt near $16B and debt multiple >2x equity; net leverage ~3.6x EBITDA per disclosures) raises interest‑rate sensitivity and constrains capital allocation. Sustained elevated debt limits the company’s ability to absorb revenue shocks, slows deleveraging options, and increases refinancing and cash‑flow strain risks over the medium term.

Material gross‑margin compression in 2025

A sharp decline in gross margin (from ~34.9% to ~26.3%) signals structural mix change and increased pass‑throughs. If persistent, lower gross margins curtail operating leverage, reduce sustainable EBITDA and free cash generation, and make funding growth, debt service, and investments more difficult without margin recovery or pricing adjustments.

Reliance on M&A and variable bookings/cancellations

Management noted meaningful contribution from acquisitions and above‑normal cancellations, and cited slowed biotech funding. Dependence on inorganic growth and variable trial execution increases volatility in organic growth and margins, making medium‑term revenue sustainability and cash conversion more contingent on successful integration and stable client funding.

IQVIA Holdings Business Overview & Revenue Model

Company Description

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

How the Company Makes Money

IQVIA makes money by selling contracted services and technology solutions primarily to life sciences customers, with revenue largely generated from service fees under multi-month or multi-year agreements. Its key revenue streams include: (1) Research & Development Solutions (R&DS): revenue from contract research organization (CRO) activities such as clinical trial design and management, site and patient engagement support, monitoring, data management, biostatistics, and related development services; these are typically billed based on project milestones, pass-through costs, and time-and-materials or fixed-fee arrangements depending on the engagement structure. (2) Technology & Analytics Solutions (TAS): revenue from providing access to healthcare data sets, data linkage, real-world evidence and advanced analytics, and software/technology platforms used for commercial operations and evidence generation; monetization commonly occurs via subscriptions, licenses, and analytics/consulting service engagements. (3) Contract Sales & Medical Solutions (CSMS): revenue from outsourced commercial services such as field sales teams, nurse educators, patient support programs, and certain medical/commercial operations support, generally earned via service fees under outsourcing contracts. Across these streams, earnings are influenced by the volume and complexity of customer projects (e.g., clinical development pipeline activity), renewals and expansion of analytics/technology subscriptions, and the company’s ability to leverage its data assets and technology platforms to deliver higher-value services. Specific partnership terms or customer concentration details are null.

IQVIA Holdings Financial Statement Overview

Summary

Profitability and earnings power have improved since 2020 and cash generation remains solid, but the balance sheet is highly leveraged (debt >2x equity; rising debt) and 2025 showed pressure with a sharp gross-margin drop and a step down in free cash flow versus 2024.

Income Statement

Revenue has expanded steadily from $11.36B (2020) to $16.31B (2025), but growth slowed materially in 2024 (~2.8%) and remained modest in 2023–2022 (~3.9%). Profitability is solid and improving versus earlier years: net margin rose from ~2.5% (2020) to ~8.3% (2025), and operating profitability remains healthy (2025 EBIT margin ~14.2%, EBITDA margin ~21.2%). The main concern is margin compression in 2025 (gross margin ~26.3% vs ~34.9% in 2024), which pressures earnings quality if it persists despite higher revenue.

Balance Sheet

The balance sheet is leveraged: total debt increased to $16.17B (2025) from $14.16B (2024), with debt running about 2.49x equity in 2025 (consistently >2x across the period). Equity is positive and has grown to $6.50B, and returns on equity are strong (~21% in 2025), indicating effective profitability on the capital base. However, the combination of rising debt and high leverage reduces flexibility and increases sensitivity to higher rates or earnings volatility.

Cash Flow

Cash generation is generally solid: operating cash flow was $2.65B and free cash flow was $2.05B in 2025, with free cash flow consistently covering a large portion of net income (about 70–78% across years; ~77% in 2025). The key weakness is volatility and a recent step down in free cash flow (2025 down ~22% vs 2024), which contrasts with the relatively stable earnings profile. Operating cash flow relative to debt is moderate (about 32% in 2025), suggesting debt reduction would likely require multiple years of steady cash flow.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.31B	15.40B	14.98B	14.41B	13.87B
Gross Profit	4.29B	5.38B	5.24B	5.03B	4.64B
EBITDA	3.46B	3.45B	3.26B	2.91B	2.77B
Net Income	1.36B	1.37B	1.36B	1.09B	966.00M
Balance Sheet
Total Assets	29.94B	26.90B	26.68B	25.34B	24.69B
Cash, Cash Equivalents and Short-Term Investments	2.14B	1.84B	1.50B	1.31B	1.48B
Total Debt	16.17B	14.16B	13.90B	13.01B	12.44B
Total Liabilities	23.31B	20.83B	20.57B	19.57B	18.65B
Stockholders Equity	6.50B	6.07B	6.11B	5.76B	6.04B
Cash Flow
Free Cash Flow	2.05B	2.11B	1.50B	1.59B	2.30B
Operating Cash Flow	2.65B	2.72B	2.15B	2.26B	2.94B
Investing Cash Flow	-2.31B	-1.44B	-1.60B	-2.01B	-2.10B
Financing Cash Flow	-150.00M	-878.00M	-382.00M	-329.00M	-1.24B

IQVIA Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 166.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IQV, the sentiment is Negative. The current price of 166.47 is below the 20-day moving average (MA) of 169.94, below the 50-day MA of 197.32, and below the 200-day MA of 195.38, indicating a bearish trend. The MACD of -6.99 indicates Negative momentum. The RSI at 39.30 is Neutral, neither overbought nor oversold. The STOCH value of 26.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IQV.

IQVIA Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDP	76 Outperform	$13.08B	35.91	118.82%	―	13.88%	23.92%
ICLR	70 Outperform	$7.49B	1,437.41	6.32%	―	-2.46%	-17.89%
DGX	70 Neutral	$21.33B	19.65	13.88%	1.80%	13.74%	14.87%
DHR	67 Neutral	$134.43B	44.80	6.99%	0.53%	2.90%	-4.81%
TMO	61 Neutral	$174.68B	32.34	13.15%	0.30%	3.91%	7.09%
IQV	59 Neutral	$28.25B	28.49	22.28%	―	3.85%	-4.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%